In an open letter, 22 experts who designed and ran Replimmune’s Phase III IGNYTE trial answered the FDA’s issues, as outlined ...

Bristol Myers Squibb (BMS) and Bain Capital have created an independent biopharmaceutical company to develop immunology ...

Pfizer (NYSE:PFE) stock gains as the company surpasses Q2 2025 expectations with $14.7B revenue and raises its full-year ...

Princeton: Bristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental ...

The trade war between China and the US is entering the next round and reaching a new peak. The Middle Kingdom is restricting ...

U.S. drugmaker Pfizer on Tuesday raised its full-year profit forecast on strong demand for its heart disease drug, Vyndaqel, ...

Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than ...

Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) will be announcing earnings results this Wednesday before the bell.

Resting-state EEG (RS-EEG) has emerged as a non-invasive, low-cost tool for Alzheimer’s disease (AD) diagnosis and ...

Converging evidence supports a key pathogenic role of the glymphatic system in the accumulation of pathological aggregates in ...

Bristol Myers Squibb offers a 5.6% dividend yield, strong cash flow, and AI-driven growth potential. See why I see this as a ...

Central Indiana’s radiopharmaceutical industry continues to expand rapidly, earning the state a new title from the U.S.